1. Scrip
  2. >>Business
  3. >>Financing

Flush With Fresh Funds, ReViral CEO Outlines RSV Trial Plans

 
• By Sten Stovall

Biotech's CEO says its lead respiratory candidate RV521 has 'caught up with rivals' in efficacy and safety.

SC1808_Sick Boy_730035700_1200.jpg
ReViral to test RV521 in babies aged one to 24 months. • Source: Shutterstock

ReViral Ltd. will use the $55m newly raised in a Series B Financing to begin a global, multi-center Phase IIa trial next year testing its lead asset RV521 in babies suffering from respiratory syncytial virus (RSV), and then move the investigational compound into adult stem cell transplant patients later in 2019, its CEO told Scrip.

The Series B financing, jointly led by New Leaf Venture Partners and Novo Ventures, had additional new investment from Perceptive Advisors while ReViral's existing investors Andera Partners, OrbiMed and Brace Pharma Capital also

More from Financing

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

More from Business

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.